What is Roka Bioscience?
Headquartered in Warren, New Jersey, Roka Bioscience, Inc. specializes in the development and commercialization of advanced molecular assay technologies. The firm's core offering, the Atlas instrument, provides a fully automated, integrated platform for the detection of foodborne pathogens, including Salmonella, Listeria, and E. coli. By automating the entire molecular diagnostic workflow, Roka serves a diverse client base comprising food processors, third-party contract testing laboratories, and government regulatory authorities. The company's market position is defined by its focus on high-throughput, reliable diagnostic solutions that enhance safety protocols across the food supply chain.
How much funding has Roka Bioscience raised?
Roka Bioscience has raised a total of $150M across 4 funding rounds:
Series C
$20M
Series D
$47.5M
Stock Offering
$60M
Share Placement
$22.5M
Series C (2011): $20M with participation from OrbiMed, TPG Biotech, New Enterprise Associates, and Gen-Probe
Series D (2012): $47.5M led by OrbiMed, TPG Biotech, Aisling Capital, and New Enterprise Associates
Stock Issuance/Offering (2014): $60M, investors not publicly disclosed
Share Placement (2016): $22.5M, investors not publicly disclosed
Key Investors in Roka Bioscience
OrbiMed
OrbiMed Advisors LLC is a specialized investment firm focused on the healthcare sector, managing capital across biopharmaceuticals, medical devices, and diagnostics to support innovation cycles.
TPG Biotech
TPG is a global alternative asset management firm with extensive experience in growth equity and life sciences, partnering with businesses to drive long-term value creation.
New Enterprise Associates
New Enterprise Associates is a prominent venture capital firm established in 1977, dedicated to supporting entrepreneurs in building transformative businesses across various sectors.
What's next for Roka Bioscience?
With the support of its recent strategic financing, Roka Bioscience is positioned to further penetrate the food safety market by expanding the utility of its Atlas detection assays. The company's strategic roadmap likely involves scaling its commercial operations and enhancing the diagnostic capabilities of its integrated platform to meet evolving regulatory requirements. As the industry shifts toward more rapid and precise pathogen identification, Roka's focus on automation and high-performance molecular testing will be critical in maintaining its competitive edge. Future growth will likely center on deepening market adoption among large-scale food processors and strengthening its presence in international testing markets, ensuring that its diagnostic infrastructure remains the standard for food safety compliance.
See full Roka Bioscience company page
